Please use this identifier to cite or link to this item: https://doi.org/10.1002/hep.22414
Title: Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B
Authors: Marcellin, P.
Chang, T.-T.
Lee Lim, S.G. 
Sievert, W.
Tong, M.
Arterburn, S.
Borroto-Esoda, K.
Frederick, D.
Rousseau, F.
Issue Date: Sep-2008
Citation: Marcellin, P., Chang, T.-T., Lee Lim, S.G., Sievert, W., Tong, M., Arterburn, S., Borroto-Esoda, K., Frederick, D., Rousseau, F. (2008-09). Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 48 (3) : 750-758. ScholarBank@NUS Repository. https://doi.org/10.1002/hep.22414
Abstract: Treatment of 171 patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) with adefovir dipivoxil (ADV) 10 mg over 48 weeks resulted in significant histological, virological, serological, and biochemical improvement compared with placebo. The long-term efficacy and safety of ADV in a subset of these patients was investigated for up to 5 years. Sixty-five patients given ADV 10 mg in year 1 elected to continue in a long-term safety and efficacy study (LTSES). At enrollment, the 65 LTSES patients were a median 34 years old, 83% male, 74% Asian, 23% Caucasian, median baseline serum hepatitis B virus (HBV) DNA 8.45 log10 copies/mL, and median baseline alanine aminotransferase (ALT) 2.0 x upper limit of normal. At 5 years on study, the median changes from baseline in serum HBV DNA and ALT for the 41 patients still on ADV were 4.05 log10 copies/mL and - 50 U/L, respectively. HBeAg loss and seroconversion were observed in 58% and 48% of patients by end of study, respectively. Fifteen patients had baseline and end of follow-up liver biopsies; improvements in necroinflammation and fibrosis were seen in 67% and 60% of these patients, respectively. Adefovir resistance mutations A181V or N236T developed in 13 LTSES patients; the first observation was at study week 195. There were no serious adverse events related to ADV. Conclusion: Treatment with ADV beyond 48 weeks was well tolerated and produced long-term virological, biochemical, serological, and histological improvement. Copyright © 2008 by the American Association for the Study of Liver Diseases.
Source Title: Hepatology
URI: http://scholarbank.nus.edu.sg/handle/10635/132798
ISSN: 02709139
DOI: 10.1002/hep.22414
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

238
checked on Jul 16, 2019

WEB OF SCIENCETM
Citations

205
checked on Jul 16, 2019

Page view(s)

11
checked on Jul 19, 2019

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.